tiprankstipranks
Trending News
More News >
OssDsign AB (SE:OSSD)
:OSSD
Sweden Market
Advertisement

OssDsign AB (OSSD) AI Stock Analysis

Compare
0 Followers

Top Page

SE:OSSD

OssDsign AB

(OSSD)

Rating:57Neutral
Price Target:
kr15.50
▲(3.61% Upside)
OssDsign AB's overall stock score is driven by strong revenue growth and improved gross margins, which are offset by persistent losses and negative cash flows. Technical indicators suggest a neutral trend with limited momentum. Valuation challenges due to ongoing losses further impact the score.

OssDsign AB (OSSD) vs. iShares MSCI Sweden ETF (EWD)

OssDsign AB Business Overview & Revenue Model

Company DescriptionOssDsign AB (publ) designs, manufactures, and sells implants and material technology for bone regeneration in Sweden, Germany, the United States, the United Kingdom, rest of Europe, and internationally. The company's products include OSSDSIGN cranial, an implant solution and related accessories for skull defect reconstruction in cranioplasty patients; and OSSDSIGN facial to treat post-traumatic skeletal deformities and congenital skeletal defects. It also offers OSSDSIGN Cranioplug for bone flap fixation and burr hole coverage; and OssDsign Catalyst, a nanosynthetic bone graft substitute that stimulates the formation of healthy bone tissue. The company was incorporated in 2011 and is headquartered in Uppsala, Sweden.
How the Company Makes MoneyOssDsign AB generates revenue primarily through the sale of its specialized bone replacement products to hospitals, healthcare facilities, and surgical centers. Their products are sold directly and through distribution partnerships, focusing on markets with high demand for advanced cranial and facial reconstruction solutions. The company's revenue model is based on a combination of direct sales, distributor agreements, and collaborations with medical professionals who use OssDsign's products in surgical procedures. Strategic partnerships and continuous innovation in product offerings also play a critical role in driving its earnings.

OssDsign AB Financial Statement Overview

Summary
OssDsign AB demonstrates strong revenue growth and improved gross margins, indicating potential for future profitability. However, persistent losses and negative cash flows are significant challenges. The company's strong equity base and low leverage provide some financial stability.
Income Statement
70
Positive
OssDsign AB has shown significant revenue growth over the years, with a CAGR of approximately 35% from 2019 to 2024. The company has improved its gross profit margin, reaching 95.38% in 2024, indicating strong pricing power or cost control. However, the company remains unprofitable, with a net profit margin of -37.07% in 2024, and EBIT and EBITDA margins also remain negative. The trend of narrowing losses suggests potential for future profitability if the trajectory continues.
Balance Sheet
65
Positive
The company maintains a strong equity position with an equity ratio of 69.61% in 2024, indicating a solid capital structure. The debt-to-equity ratio is low at 0.009, showcasing low financial leverage. Despite this, the consistent negative net income impacts return on equity, which remains negative. The company has a sizable cash position, which provides financial flexibility.
Cash Flow
60
Neutral
OssDsign AB's cash flows remain challenging, with substantial negative operating cash flow and free cash flow in 2024. The operating cash flow to net income ratio is negative, indicating cash outflows exceed losses. However, the free cash flow improved slightly compared to 2023, suggesting some operational improvements. Continued negative cash flows could pose liquidity risks if not addressed.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue168.19M133.94M112.16M56.98M31.73M24.87M
Gross Profit162.66M127.75M83.64M45.13M20.84M16.00M
EBITDA-41.73M-45.31M-122.02M-89.41M-83.95M-80.64M
Net Income-45.74M-49.66M-130.49M-99.39M-93.92M-84.59M
Balance Sheet
Total Assets427.96M307.42M356.39M339.50M343.99M246.65M
Cash, Cash Equivalents and Short-Term Investments212.74M100.86M165.94M124.65M151.37M49.40M
Total Debt1.91M1.97M3.15M13.60M14.13M17.24M
Total Liabilities84.25M93.36M105.26M91.39M81.26M134.58M
Stockholders Equity343.71M214.06M251.13M248.11M262.72M112.07M
Cash Flow
Free Cash Flow-57.38M-63.04M-94.03M-89.36M-89.84M-81.59M
Operating Cash Flow-53.50M-62.38M-93.91M-89.23M-89.78M-79.10M
Investing Cash Flow-3.89M-657.00K-124.00K-129.00K-51.85M-17.67M
Financing Cash Flow152.07M-2.46M135.40M61.84M243.43M33.18M

OssDsign AB Technical Analysis

Technical Analysis Sentiment
Positive
Last Price14.96
Price Trends
50DMA
14.67
Positive
100DMA
14.03
Positive
200DMA
12.42
Positive
Market Momentum
MACD
-0.03
Positive
RSI
52.81
Neutral
STOCH
33.99
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:OSSD, the sentiment is Positive. The current price of 14.96 is above the 20-day moving average (MA) of 14.69, above the 50-day MA of 14.67, and above the 200-day MA of 12.42, indicating a bullish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 52.81 is Neutral, neither overbought nor oversold. The STOCH value of 33.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:OSSD.

OssDsign AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
57
Neutral
kr1.57B
36.23%63.14%
51
Neutral
$7.81B-0.22-40.01%2.29%21.48%-2.11%
$179.44M80.832.64%
$110.92M-35.36%
€84.52M-5.83%
€101.42M43.177.87%
€145.23M-5.40%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:OSSD
OssDsign AB
15.00
7.57
101.88%
PXMBF
Paxman AB
3.50
0.00
0.00%
SNZZF
Senzime AB
0.66
-0.12
-15.38%
DE:5JE
Bactiguard Holding AB
2.34
-3.22
-57.91%
DE:24C
C-Rad AB Class B
2.88
-0.97
-25.19%
DE:7D2A
Sedana Medical AB
1.39
-0.59
-29.80%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 29, 2025